

NeuroInvestment

NeuroInvestment is the indispensable Business Development and strategic planning tool for the pharmaceutical industry and those venture capital specialists focused on opportunities in neurotherapeutics. Here are some comments from our subscribers:

“NeuroInvestment updates provide deep insight about the product development landscape across neuroscience diseases – far greater than any other source available. Harry is not afraid to provide strong opinions on the merits of new approaches to treating diseases, or of a company’s management, but these always supported by evidence, and subsequent events usually prove the judgement to have been accurate. And all this is provided in a unique style that makes for enjoyable reading – quite an achievement.

There is nothing comparable that I am aware of in any other therapeutic area. People look forward to the start of a month – if I haven’t forwarded on the next copy of NeuroInvestment by the end of the first day, I always receive emails asking where it is!”

**Global Strategy Director, Neurosciences
A Top Five Pharmaceutical Company (who requested to not be identified)**

“NeuroInvestment is informative, thoughtful, well researched, and refreshingly irreverent... a must read for individuals involved in the business of neuroscience.”

**Chris Fibiger PhD
Chief Scientific Officer
Biovail**

“Brilliant, timely, thoroughly researched, witty and always insightful. No morning note, scientific review article or thought leader interview can match this, in my opinion.”

**P. Murali Doraiswamy MD
Division Head, Biological Psychiatry
Duke University Medical Center**

“Ferghana considers NeuroInvestment an extremely useful business intelligence tool, providing us with news and views on business, science and clinical topics in the complex field of neuroscience. In fact, we would like to find something similar in the other therapeutic sectors of interest to us...but NI is unique and thus greatly appreciated for its witty, insightful commentary and straightforward analyses.”

**William J Kridel Jr
Managing Director
Ferghana Partners**

“NeuroInvestment is the best publication NEA uses for pharmaceuticals in the CNS space .. It is a great way to keep up with companies, trends, and deals in the CNS area. We believe the next 20 years will lead to many new exciting developments for CNS companies so we value the relationships that have been built with the NeuroInvestment staff.”

**Charles Newhall
Managing Director
New Enterprise Associates**

“I am delighted to recommend NeuroInvestment. It is extremely well-written, pithy, and informative. I have found it to be accurate and it is also a great source of information about new drugs under development. I am always impressed by how well-researched each topic is. Dr. Tracy is the Shakespeare of Neuroscience.”

**Flint Beal MD PhD
Professor of Neurology and Neuroscience
Cornell Medical College**